Gene therapy trial for HIV and lymphoma shows early safety results

This early-phase study tested a new gene therapy approach in 2 HIV patients who also had high-risk lymphoma. The therapy involved taking the patients' own blood stem cells and immune cells, adding a protective gene (Cal-1) to make them resistant to HIV, and then giving them back after chemotherapy. The main goals were to check if the procedure was safe and if the modified cells could survive in the body. Because HIV requires ongoing management, this is not a cure but a way to better control the disease.